EGF receptor in neoplasia and metastasis

Khashayarsha Khazaie, Volker Schirrmacher, Rosemarie B. Lichtner

Research output: Contribution to journalArticlepeer-review

264 Scopus citations


EGFR is a member of the tyrosine kinase family of cell surface receptors with a wide range of expression throughout development and in a variety of different cell types. The receptor can transmit signals to cells: i) upon interaction with ligands such as EGF, TGFα, amphiregulin or heparin binding EGF, ii) upon truncation or mutation of extracellular and/or intracellular domains, iii) upon amplification of a basal receptor activity (in the absence of ligand) through cooperation with other cellular signaling pathways or nuclear events (e.g. expression of v-erbA). The activated EGFR can exert pleiotropic functions on cells, depending on their tissue origin and state of differentiation. Under certain conditions it can also contribute to neoplasia and development of metastases. Such conditions can exist upon aberrant receptor/ligand expression and activation (e.g. in the wrong cell; at the wrong time; in the wrong amounts). Aberrant signalling can also occur through constitutive EGFR activation. Oncogenic potential of EGFR has been demonstrated in a wide range of experimental animals. EGFR is also implicated in human cancer, where it may contribute both to the initiation (glioblastoma) and progression (epithelial tumors) of the disease. EGFR may influence key steps in the processes of tumor invasion and dissemination. Involvement of EGFR in tumor spread may indicate a potential use of this receptor as a target for antimetastatic therapy.

Original languageEnglish (US)
Pages (from-to)255-274
Number of pages20
JournalCancer and Metastasis Reviews
Issue number3-4
StatePublished - Sep 1993


  • EGFR
  • metastasis
  • neoplasia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'EGF receptor in neoplasia and metastasis'. Together they form a unique fingerprint.

Cite this